Clinical Trials

    Showing 1 - 10 of 10 Neurodegenerative Diseases

    18F-MK-6240 Tau PET and Brain Inflammation in Alzheimer’s Disease

    Status: Enrolling

    Investigator: Joseph Masdeu

    Study Coordinator: Nilene Crisci

    Phone: 713.441.3771

    To clarify the role of inflammation in the pathogenesis of AD, it is important to measure inflammation in brain of people with AD and its relationship with abnormal tau, as the disease progresses. So far, there is no in vivo data in humans verifying ... Read more >

    A Phase I Trial to Evaluate Safety and Tolerability of Abatacept followed by Subcutaneous Interleukin-2 Administration in Patients with Amyotrophic Lateral Sclerosis

    Status: Enrolling

    Investigator: Sheetal Shroff

    Study Coordinator: KaDeesia Brown

    Phone: 713.441.9120

    In Amyotrophic Lateral Sclerosis (ALS), the reduction of regulatory T lymphocyte (Treg) numbers and suppressive function correlates with rapid disease progression. We completed a phase 1 study of infusions of expanded autologous Tregs in combination ... Read more >

    A Study of Biological Markers for the Nervous and Immune Systems and Free Radical Mediated Processes in Amyotrophic Lateral Sclerosis (ALS)

    Status: Enrolling

    Investigator: Stanley Appel

    Study Coordinator: Aramide Balogun

    Phone: 713.441.6955

    The purpose of this protocol is to develop and maintain a biospecimen bank comprised of blood, urine, CSF collected during diagnostic evaluations, tissue from biopsies and autopsies collected from patients with neurological disease and non-neurolog... Read more >

    A Study to Perform Apheresis (Leukapheresis) on Patients with Amyotrophic Lateral Sclerosis to Collect Regulatory T-Lymphocytes (Tregs)

    Status: Enrolling

    Investigator: Sheetal Shroff

    Study Coordinator:

    Phone:

    This leukapheresis study proposes to continue our work in developing and optimizing our Treg manufacturing process. Under this study, up to 10 patients with ALS will undergo leukapheresis. Their Tregs will subsequently be isolated and expanded fr... Read more >

    AC-058B201 Echocardiographic Ancillary Study

    Status: Open Not Enrolling

    Investigator: Sherif Nagueh

    Study Coordinator: Nirali Patel

    Phone: 713.441.2116

    Multicenter, Randomized, Double-blind, Parallel-group Extension to Study AC-058B201 to Investigate the Long-term Safety, Tolerability, and Efficacy of Three Doses of ACT-128800, an Oral S1P1 Receptor Agonist, in Patients With Relapsing-remitting Mult... Read more >

    ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)

    Status: Enrolling

    Investigator: Maria Pascual

    Study Coordinator: Victoria Arbones

    Phone: 713.441.7650

    The ARTFL LEFFTDS Longitudinal Frontotemporal Dementia (ALLFTD) study aims to evaluate sporadic (s-) and familial (f-) frontotemporal lobar degeneration (FTLD) patients and asymptomatic family members of f-FTLD patients, characterizing the cohorts lo... Read more >

    ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis) (ConTTRibute)

    Status: Enrolling

    Investigator: Sheetal Shroff

    Study Coordinator: KaDeesia Brown

    Phone: 713.441.9120

    The purpose of this study is to: Describe epidemiological and clinical characteristics, natural history and real-world clinical management of ATTR amyloidosis patients Characterize the safety and effectiveness of patisiran and vutrisiran as part ... Read more >

    HEALEY ALS Platform Trial

    Status: Enrolling

    Investigator: Sheetal Shroff

    Study Coordinator:

    Phone:

    The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS.... Read more >

    Long-Term, Observational, Registry of Patients With Generalized Myasthenia Gravis Who Have Received Treatment With Complement C5 Inhibition Therapies

    Status: Enrolling

    Investigator: Ericka Greene

    Study Coordinator: KaDeesia Brown

    Phone: 713.441.9120

    Complement component 5 (C5) inhibition therapies have been available for patients with generalized Myasthenia Gravis (gMG) in the United States since the introduction of Soliris® in late 2017. Alexion is developing potential new therapies that leve... Read more >

    Role of Brain Inflammation in Alzheimer’s Disease

    Status: Enrolling

    Investigator: Joseph Masdeu

    Study Coordinator: Nilene Crisci

    Phone: 713.441.3771

    The discovery of AD risk genes coding for proteins involved in inflammation has revived the interest in neuroinflammation (or brain inflammation) in the pathogenesis of AD. To understand the role of inflammation in the pathogenesis of AD, it is impor... Read more >